Sedana Medical: Confusing clinical data - Redeye

Redeye comments on the clinical data from the SESAR study and the confusion it brought. We argue that management’s details and explanation are feasible, and its commercial outlook (using isoflurane) is intact. Moreover, the subgroup is a relatively low portion of Sedana’s targeted patient group, and further subanalysis could provide additional insights. Still, we do not regard this as a curtain-down event, though communication regarding the SESAR study from the company indeed added to the confusion in the stock these past two days.

Länk till analysen i sin helhet: https://www.redeye.se/research/1089267/sedana-medical-confusing-clinical-data?utm_source=finwire&utm_medium=RSS